New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:13 EDTMGNXMacroGenics price target raised to $51 from $35 at Stifel
Stifel increased its price target on MacroGenics as the firm thinks the company is uniquely positioned to benefit from investor enthusiasm for targeted combination therapy in the immuno-oncology space. The firm believes the company has best-in-class technology, while recent data has increased Stifel's confidence in the company's approach. It keeps a Buy rating on the shares.
News For MGNX From The Last 14 Days
Check below for free stories on MGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
17:20 EDTMGNXMacroGenics IND MGD007 cleared by FDA to start enrolling patients
MacroGenics announced that its investigational new drug, or IND, for MGD007 has been cleared by the FDA to proceed with the phase 1 human clinical trial for this drug candidate. MGD007 is a Dual-Affinity Re-Targeting protein being developed for the treatment of colorectal cancer. MacroGenics will receive a $5M milestone payment from Servier, France's largest privately-held pharmaceutical company, triggered by the IND clearance.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use